This study investigates pancreatic cancer. The purpose of this study is to explore adaptive neoadjuvant chemotherapy in patients with resectable and borderline resectable pancreatic cancer.
The study evaluates how well the adaptive approach works. It looks at treatment response using clinical assessments, imaging, and biomarkers. It evaluates the safety and effectiveness of changing treatments based on these responses.
- Who can participate: Participants must be 18 years or older with resectable or borderline resectable pancreatic cancer, have a good performance status, and adequate organ function.
- Study details: Participants will receive adaptive chemotherapy based on treatment response. Some may receive chemoradiation or surgery.
How understandable was the trial content above?
Hard to understand
Easy to understand